Suyash Prasad

Summary

Publications

  1. ncbi request reprint A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD)
    Suyash Prasad
    Dept Neurosciences, Eli Lilly and Co Ltd, Basingstoke, UK
    Curr Med Res Opin 23:379-94. 2007
  2. ncbi request reprint The provision and nature of ADHD services for children/adolescents in the UK: results from a nationwide survey
    Michael Tettenborn
    Frimley Children s Centre, UK
    Clin Child Psychol Psychiatry 13:287-304. 2008
  3. ncbi request reprint Switching from neurostimulant therapy to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder : clinical approaches and review of current available evidence
    Suyash Prasad
    Department of Paediatrics, Cromwell Hospital, London, UK
    Paediatr Drugs 10:39-47. 2008
  4. doi request reprint Assessing the value of atomoxetine in treating children and adolescents with ADHD in the UK
    S Prasad
    Department Paediatrics, Cromwell Hospital, London, UK
    Int J Clin Pract 63:1031-40. 2009
  5. ncbi request reprint Atomoxetine hydrochloride and executive function in children with attention-deficit/hyperactivity disorder
    Joanne Barton
    J Child Adolesc Psychopharmacol 15:147-9. 2005

Collaborators

  • David Coghill
  • Michael Tettenborn
  • Joanne Barton
  • Sarah Jenkins
  • Chris Steer
  • Nikos Myttas
  • Anne McClure
  • Joanne Parker
  • Arthur Speight
  • Somnath Banerjee
  • Senerath Perera
  • Mohan Chandola
  • Ian Male
  • John Dearlove
  • Kanagasabai Puvanendran
  • Chunnaiah Yemula
  • Jorge Arellano
  • Valerie Harpin
  • Saroj Jamdar
  • Geetha Kugan
  • Karina Hart
  • Baljinder Singh
  • Nigel Speight
  • Stephen Ralston
  • Chelvi Kukendra
  • Duncan Manders
  • Lynne Poole
  • Christopher Steer
  • Louise Timlin
  • Avninder Spencer
  • Patricia Mooney

Detail Information

Publications5

  1. ncbi request reprint A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD)
    Suyash Prasad
    Dept Neurosciences, Eli Lilly and Co Ltd, Basingstoke, UK
    Curr Med Res Opin 23:379-94. 2007
    ....
  2. ncbi request reprint The provision and nature of ADHD services for children/adolescents in the UK: results from a nationwide survey
    Michael Tettenborn
    Frimley Children s Centre, UK
    Clin Child Psychol Psychiatry 13:287-304. 2008
    ..Results of the survey provide an important insight into the ADHD-related services provided by ADORE centres, as well as highlighting the availability and limitations of such services...
  3. ncbi request reprint Switching from neurostimulant therapy to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder : clinical approaches and review of current available evidence
    Suyash Prasad
    Department of Paediatrics, Cromwell Hospital, London, UK
    Paediatr Drugs 10:39-47. 2008
    ..We conclude that patients with ADHD can be switched from neurostimulants, specifically methylphenidate, to atomoxetine, and may benefit from symptom improvement...
  4. doi request reprint Assessing the value of atomoxetine in treating children and adolescents with ADHD in the UK
    S Prasad
    Department Paediatrics, Cromwell Hospital, London, UK
    Int J Clin Pract 63:1031-40. 2009
    ..For attention-deficit/hyperactivity disorder (ADHD), economic evaluations have largely focused on pharmacotherapy, and results indicate that such treatments are cost-effective compared with other interventions...
  5. ncbi request reprint Atomoxetine hydrochloride and executive function in children with attention-deficit/hyperactivity disorder
    Joanne Barton
    J Child Adolesc Psychopharmacol 15:147-9. 2005